“…Detailed studies into early state longitudinal Alzheimer's disease marker trajectory dynamics, using data-driven methods, have the potential to aid the effort in the development of measures that can accurately and robustly quantify indications of the disease, even before its presymtomatic and preclinal stages. Previously, hypothetical [23,24] and experimental models [13,14,50,10,20,7,25,41,21,4,5,1,12,15,53] of disease progression based on Alzheimer's disease markers, such as cerebrospinal fluid (CSF), imaging and cognitive markers have been proposed.…”